Menu Back to 3rd-DIA-Cell-and-Gene-Therapy-Products-Symposium-in-Japan


Click Here to View the Program

Accelerated by new regulatory and legal systems that came into practice in 2013, the development of regenerative medicine in Japan has attracted considerable international attention. Today, research has progressed to the point that many cell therapy products are now entering clinical development by companies both within and outside Japan. This has revealed a number of issues in the development, distribution, and post-market management of these products.

DIA Japan has brought together stakeholders involved in developing cell therapy products, particularly from industry and academia, for our annual Cell Therapy Products Symposium since 2016. Its mission then, as it is now, is to exchange insights and ideas with relevant regulatory and other government authorities in order to deepen mutual understanding and resolve issues of concern about these products. Our third annual offering adds gene therapy products to its agenda, reflecting scientific progress in this area as well as requests from these stakeholders, and has been renamed as our Cell and Gene Therapy Products Symposium.

In the keynote lecture, Professor Jun Takahashi of RIKEN will talk about product development with induced pluripotent stem (iPS) cells before commercialization, and the Cabinet Office will present its perspective on the future prospects of gene therapy products in Japan.

Evolution of Japan Environment for Cell Therapy Products, the first day of this two-day symposium, will follow the frameworks from the first and second annual symposiums and cover issues from the quality and non-clinical use of cell therapy products to commercialization and post-marketing measures. These conversations will compare the current state of regulations and related frameworks between Japan, Europe, and the US.

On day two, Challenges for Gene Therapy Product Development and Manufacture in Japan, we will explore in an educational session the current state of research and development of gene therapy products in Japan. Our deep dive session will examine country-specific concerns such as the operation of biodiversity evaluation under the Cartagena Act, which requires a strategic approach to realize the practical commercialization and application of gene therapy products. International speakers have been invited for both days to share current activities and challenges in harmonized global development.

While this program has been prepared to give you the opportunity to attend either the first day or second day independently, we invite you to participate through both days; you will notice that many topics and concerns are common between both cell and gene therapy products.

The DIA Cell Therapy/Gene Therapy Product Symposium encourages open and ongoing discussion across industry, academia, and government stakeholders. We hope this Symposium will continue to grow into the best place for exchanging knowledge and sharing insights about these products and as a highly valued networking opportunity for you and your colleagues. We look forward to your active participation in Tokyo.

Who should attend?

Cell therapy/gene therapy product development professionals in biopharmaceutical companies, medical devices companies, venture capital companies, regulatory agencies, or academia.

Program Committee

  • Teruyo  Arato, PhD
    Teruyo Arato, PhD Professor, Clinical Research and Medical Innovation Center
    Hokkaido University Hospital, Japan
  • Yoji  Sato, PhD
    Yoji Sato, PhD Head, Division of Cell-Based Therapeutic Products
    National Institute of Health Sciences, Japan
  • Yasuko  Terao, PhD
    Yasuko Terao, PhD Director, Head of Research & Development Division, Clinical Science, R&D
    Janssen Pharmaceutical K.K., Japan
  • Masaki  Kasai, PhD
    Masaki Kasai, PhD Reviewer, Office of Cellular and Tissue-basaed Products
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Satoru  Hayata
    Satoru Hayata Head of Center, Rare Diseases Medicine Development Centre
    GlaxoSmithKline K.K., Japan
  • Keiji  Miyamoto
    Keiji Miyamoto Principal, Regulatory Affairs & Planning Group, New Drug Regulatory Affairs Dept
    Daiichi Sankyo Co., Ltd., Japan
  • Sumimasa  Nagai, MD, PhD
    Sumimasa Nagai, MD, PhD Senior Assistant Professor, Translational Research Center
    The University of Tokyo Hospital, Japan
  • Hiromi  Okabe, PhD
    Hiromi Okabe, PhD Manager, Global Regulatory Management Group, New Drug Regulatory Affairs Dept.
    Daiichi Sankyo Co., Ltd., Japan
  • Masafumi  Onodera, MD, PhD
    Masafumi Onodera, MD, PhD Head, Department of Human Genetics / Chief, Division of Immunology
    National Center for Child Health and Development, Japan
  • Hiroyuki  Suda
    Hiroyuki Suda Senior Director, Clinical Operation Department
    Oncolys BioPharma Inc., Japan
  • Kazuhiro  Takekita
    Kazuhiro Takekita Instructor, Department of Cardiovascular Surgery, Graduate School of Medicine,
    Osaka University, Japan
  • Yoshie  Tsurumaki
    Yoshie Tsurumaki Senior Incubator Program Manager, CTL019 Incubator Dept, Oncology Dev. & MA Dept
    Novartis Pharma K.K., Japan
  • Akiko  Ikeda, RPh
    Akiko Ikeda, RPh Senior Manager, Policy Intelligence Dept., Integrated Market Access Division
    Janssen Pharmaceutical K.K., Japan
Load More

Contact us

Please contact DIA Japan for further information.

Send Email

Digital Learning Catalog

DIA Learning: eLearning Soultions